Alessandra Larocca

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

Antonio Palumbo, Sara Bringhen, María‐Victoria Mateos et al. · Blood · 2015 · 762 citations · Full text

Medicine, Hematology, Oncology +16

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

Antonio Palumbo, Davide Rossi, Maide Cavalli et al. · Journal of Clinical Oncology · 2010 · 426 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Mattia D’Agostino, David A. Cairns, Juan José Lahuerta et al. · Journal of Clinical Oncology · 2022 · 407 citations · Full text

Medicine, Oncology, Molecular Oncology +15

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications

Evangelos Terpos, Martina Kleber, Monika Engelhardt et al. · Haematologica · 2015 · 398 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 385 citations · Full text

Medicine, Hematology, Pharmacotherapy +11